Lv1
50 积分 2024-10-15 加入
[Management of ocular adverse events associated with antibody-drug conjugates in the treatment of solid tumors: a consensus statement from Chinese experts (2025 edition)]
23天前
已完结
[Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease]
28天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
4个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
5个月前
已完结
Corneal Changes From Antibody-Drug Conjugates
5个月前
已完结
Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysis
5个月前
已完结
Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies
7个月前
已完结
皖公网安备34019202002308
